Business
Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery
PWR delivers science-driven cellular energy and recovery support as part of Jupiter’s expanding longevity supplement portfolio Jupiter, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, is pleased to unveil Nugevia™ PWR, a daily mitochondrial health supplement scientifically formulated to support cellular energy, endurance, and recov
About this update from Jupiter Neurosciences, Inc.
[{"type":"image","alt":"Jupiter Neurosciences, Inc.","displaySize":"","headline":null,"caption":"Jupiter Neurosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/5207be81de89b7ef2fba669f8dd3e7f6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pYMq4mt4Y617fyJqYqyXSg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5207be81de89b7ef2fba669f8dd3e7f6","width":300,"height":89}},"lazy":false},{"type":"text","content":"PWR delivers science-driven cellular energy and recovery support as part of Jupiter’s expanding longevity supplement portfolio","length":126,"tagName":"p"},{"type":"text","content":"Jupiter, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, is pleased to unveil Nugevia™ PWR, a daily mitochondrial health supplement scientifically formulated to support cellular energy, endurance, and recovery. PWR targets a rapidly expanding consumer demand for science-backed, clinically validated supplements, providing a high-margin growth opportunity within the longevity and wellness markets, projected to reach $8 trillion by 2030, with commercial availability expected in Fall 2025.","length":677,"tagName":"p"},{"type":"text","content":"Clinically Validated Cellular Fuel","length":34,"tagName":"p"},{"type":"text","content":"Built on the same pharmaceutical-grade delivery platform behind Jupiter's CNS drug candidates, PWR pairs JOTROL™ with a curated blend of mitochondrial support ingredients to help optimize energy production, protect against oxidative stress, and enhance physical performance. The formulation was developed for adults seeking sustained strength, metabolic resilience, and recovery support grounded in clinical science.","length":420,"tagName":"p"},{"type":"text","content":""With PWR, we are tapping into the bioenergetic core of healthy aging," said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. "By leveraging our JOTROL™ platform beyond the clinic, we're offering a science-first approach to vitality and endurance that meets growing demand from consumers who want more than just a qui...